Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Spriano

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Pharmacology & Therapeutics|July 22, 2020
Targeting BET bromodomain proteins in cancer: The example of lymphomasFilippo Spriano, Anastasios Stathis, Francesco Bertoni
Exploration of Targeted Anti-Tumor Therapy|January 19, 2023
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidencesMarilia Barreca, Noémie Lang, Chiara Tarantelli, et al.
Ejhaem|June 8, 2026
Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted TherapiesFilippo Spriano, Alberto J Arribas, Fangwen Zhang, et al.
Oncotarget|February 25, 2016
Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapyFrancesca Ricci, Maddalena Fratelli, Federica Guffanti, et al.
Chembiochem : a European Journal of Chemical Biology|September 11, 2025
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell LymphomaLaurence K Jennings, Filippo Spriano, Maggie M Reddy, et al.
Molecular Cancer Therapeutics|May 9, 2019
DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell LymphomasValentina Restelli, Monica Lupi, Rosaria Chilà, et al.
Chemmedchem|April 1, 2025
Development of C646-Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300Francesco Fiorentino, Filippo Spriano, Daniela Tomaselli, et al.
Journal of Clinical Medicine|January 21, 2023
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK InhibitorsFrancesca Guidetti, Alberto J Arribas, Giulio Sartori, et al.
Cancer Medicine|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaFilippo Spriano, Luciano Cascione, Chiara Tarantelli, et al.
American Journal of Cancer Research|June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma modelsFilippo Spriano, Luca Aresu, Luciano Cascione, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Pharmacology & Therapeutics|July 22, 2020
Targeting BET bromodomain proteins in cancer: The example of lymphomasFilippo Spriano, Anastasios Stathis, Francesco Bertoni
Exploration of Targeted Anti-Tumor Therapy|January 19, 2023
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidencesMarilia Barreca, Noémie Lang, Chiara Tarantelli, et al.
Ejhaem|June 8, 2026
Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted TherapiesFilippo Spriano, Alberto J Arribas, Fangwen Zhang, et al.
Oncotarget|February 25, 2016
Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapyFrancesca Ricci, Maddalena Fratelli, Federica Guffanti, et al.
Chembiochem : a European Journal of Chemical Biology|September 11, 2025
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell LymphomaLaurence K Jennings, Filippo Spriano, Maggie M Reddy, et al.
Molecular Cancer Therapeutics|May 9, 2019
DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell LymphomasValentina Restelli, Monica Lupi, Rosaria Chilà, et al.
Chemmedchem|April 1, 2025
Development of C646-Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300Francesco Fiorentino, Filippo Spriano, Daniela Tomaselli, et al.
Journal of Clinical Medicine|January 21, 2023
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK InhibitorsFrancesca Guidetti, Alberto J Arribas, Giulio Sartori, et al.
Cancer Medicine|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaFilippo Spriano, Luciano Cascione, Chiara Tarantelli, et al.
American Journal of Cancer Research|June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma modelsFilippo Spriano, Luca Aresu, Luciano Cascione, et al.
Pageof 4